Switch theme
Sign up to access all valuation multiples
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
2008
n/a
LTM Revenue $127M
LTM EBITDA $53.8M
$18.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alteogen has a last 12-month revenue (LTM) of $127M and a last 12-month EBITDA of $53.8M.
In the most recent fiscal year, Alteogen achieved revenue of $75.4M and an EBITDA of $29.4M.
Alteogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alteogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $127M | XXX | $75.4M | XXX | XXX | XXX |
| Gross Profit | $92.5M | XXX | $47.0M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $53.8M | XXX | $29.4M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 39% | XXX | XXX | XXX |
| EBIT | $62.9M | XXX | $18.6M | XXX | XXX | XXX |
| EBIT Margin | 50% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $65.5M | XXX | $45.6M | XXX | XXX | XXX |
| Net Margin | 52% | XXX | 61% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Alteogen's stock price is KRW 486000 (or $356).
Alteogen has current market cap of KRW 25.90T (or $19.0B), and EV of KRW 25.58T (or $18.8B).
See Alteogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18.8B | $19.0B | XXX | XXX | XXX | XXX | $1.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Alteogen has market cap of $19.0B and EV of $18.8B.
Alteogen's trades at 248.7x EV/Revenue multiple, and 637.4x EV/EBITDA.
Equity research analysts estimate Alteogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alteogen has a P/E ratio of 289.8x.
See valuation multiples for Alteogen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.0B | XXX | $19.0B | XXX | XXX | XXX |
| EV (current) | $18.8B | XXX | $18.8B | XXX | XXX | XXX |
| EV/Revenue | 148.1x | XXX | 248.7x | XXX | XXX | XXX |
| EV/EBITDA | 348.6x | XXX | 637.4x | XXX | XXX | XXX |
| EV/EBIT | 298.0x | XXX | 1007.1x | XXX | XXX | XXX |
| EV/Gross Profit | 202.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 289.8x | XXX | 416.1x | XXX | XXX | XXX |
| EV/FCF | 312.8x | XXX | 894.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlteogen's last 12 month revenue growth is 165%
Alteogen's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Alteogen's rule of 40 is 165% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alteogen's rule of X is 454% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alteogen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 165% | XXX | 151% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | 288% | XXX | 1492% | XXX | XXX | XXX |
| Rule of 40 | 165% | XXX | 204% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 454% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alteogen acquired XXX companies to date.
Last acquisition by Alteogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Alteogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alteogen founded? | Alteogen was founded in 2008. |
| Where is Alteogen headquartered? | Alteogen is headquartered in South Korea. |
| Who is the CEO of Alteogen? | Alteogen's CEO is Mr. Soon-Jae Park. |
| Is Alteogen publicy listed? | Yes, Alteogen is a public company listed on KRX. |
| What is the stock symbol of Alteogen? | Alteogen trades under 196170 ticker. |
| When did Alteogen go public? | Alteogen went public in 2014. |
| Who are competitors of Alteogen? | Similar companies to Alteogen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alteogen? | Alteogen's current market cap is $19.0B |
| What is the current revenue of Alteogen? | Alteogen's last 12 months revenue is $127M. |
| What is the current revenue growth of Alteogen? | Alteogen revenue growth (NTM/LTM) is 165%. |
| What is the current EV/Revenue multiple of Alteogen? | Current revenue multiple of Alteogen is 148.1x. |
| Is Alteogen profitable? | Yes, Alteogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alteogen? | Alteogen's last 12 months EBITDA is $53.8M. |
| What is Alteogen's EBITDA margin? | Alteogen's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of Alteogen? | Current EBITDA multiple of Alteogen is 348.6x. |
| What is the current FCF of Alteogen? | Alteogen's last 12 months FCF is $60.0M. |
| What is Alteogen's FCF margin? | Alteogen's last 12 months FCF margin is 47%. |
| What is the current EV/FCF multiple of Alteogen? | Current FCF multiple of Alteogen is 312.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
